Dendreon is a biotechnology company that develops immunotherapy treatments for cancer. The company was founded in 1992 and is headquartered in Seattle, Washington. Dendreon's flagship product, Provenge, is an immunotherapy treatment for prostate cancer that was approved by the FDA in 2010. The company has faced financial difficulties in recent years, including filing for bankruptcy in 2014. In 2017, Dendreon was acquired by Chinese conglomerate, Sanpower Group.